Clinical Trial Update: Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old) [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety and immunogenicity of three formulations of the Vi-CRM197 typhoid conjugate vaccine in adults aged 18-40; results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Typhoid Fever

Drugs mentioned

• Vi-CRM197 vaccine (Vi-CRM197 conjugate vaccine)

Snippet

Sponsor: Novartis | Conditions: Typhoid Fever | Phase 2 | Status: COMPLETED | Results posted: 2012-04-03